Mitochondrial dysfunction pathway

The mitochondrial dysfunction pathway is not a single molecule or receptor but rather a collection of interconnected molecular events involving impaired mitochondrial function. This pathway encompasses disruptions in energy production (ATP synthesis), increased oxidative stress due to reactive oxygen species accumulation, altered apoptosis signaling via the intrinsic/mitochondrial route, changes in calcium handling, defective mitophagy/autophagy processes, and abnormal mitochondria-nuclear communication. These dysfunctions are implicated as central mechanisms across a wide spectrum of diseases including cancer—where they influence cell survival and drug resistance—neurodegenerative disorders such as Parkinson's and Alzheimer's disease through neuronal loss mechanisms; cardiovascular diseases by affecting vascular health; metabolic syndromes like diabetes; as well as rare genetic conditions involving primary defects in mitochondrial proteins or translation machinery. While many drugs target components within these pathways to restore normal function or induce selective cell death in diseased cells—for example by promoting cytochrome c release from mitochondria—the “mitochondrial dysfunction pathway” itself is not considered a discrete therapeutic target but rather an umbrella term describing multiple potential intervention points within cellular bioenergetics and survival networks. Note: The entry "Mitochondrial dysfunction pathway" is not the name of a specific molecule/receptor but refers broadly to disrupted cellular processes involving mitochondria. It should not be treated as a canonical drug target entity.

Induction of apoptosis via mitochondrial membrane permeabilization and cytochrome c release (e.g., paclitaxel, ursolic acid); Modulation of oxidative phosphorylation or electron transport chain activity (e.g., methylene blue); Enhancement of mitophagy or mitochondrial biogenesis through NAD+/NADH modulation or AMPK activation (e.g., nicotinamide, resveratrol)